Nanosuspension Of Poorly Soluble Anti-Diabetic Drug For Enhancement Of Solubility And Dissolution

Abstract

As an inhibitor of sodium-glucose co-transporter-2 in the renal tubules, tolbutamide is an anti-diabetic medication used in the adjuvant therapy for type-II diabetes.  "Limitations in formulation development and therapeutic plasma concentration are evidenced by the drug's poor solubility and permeability.  The research aimed to develop a surfactant-stabilized nanosuspension formulation that would increase the drug's solubility and dissolving rate in the body.  Poly vinyl alcohol and Pluronic were used as surfactants in 1%, 3%, and 5% concentrations to create nanoparticles by the nanoprecipitation-solvent evaporation process.  Nano-sized (81-117 nm), monodisperse, and zeta-potential-stable particles were seen in Pluronic-optimized formulations.   In comparison to the pure drug aqueous dispersion, the nanosuspension generated with 1% and 3% Pluronic F127 increased drug solubility by a factor of 2 and 5, respectively.  FTIR and TG-DSC studies indicated that the drug and surfactant displayed weak interactions due to hydrogen bonding and hydrophobic interactions, which facilitated the creation of stable nanoparticles.  The SEM confirmed the creation of spherical nanoparticles with smooth surfaces.  As a result, it is clear that developing Tolbutamide nanoformulation was an optimised method to improve drug dispersion